- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8 - K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (D)
Of the
SECURITIES EXCHANGE ACT OF 1934
Date of Report: MARCH 31, 2003
ENDOVASC, INC.
(Exact name of registrant as specified in its charter)
NEVADA
(State or other jurisdiction of incorporation or organization)
000-28371 76-0512500
(Commission File Number) (IRS Employer Identification Number)
DR. DAVID P. SUMMERS, CHAIRMAN & CEO
ENDOVASC, INC.
15001 WALDEN ROAD, SUITE 108
MONTGOMERY, TEXAS 77356
(Address of principal executive offices)
(936) 448-2222
(Registrant's telephone number, including area code)
15001 WALDEN ROAD, SUITE 108
MONTGOMERY, TEXAS 77356
(Former name or former address, if changed since last report)
- --------------------------------------------------------------------------------
ITEM 1. MERGER OR DISPOSITION OF ASSETS
- ---------------------------------------
On February 24, 2003, Endovasc Ltd., Inc., Delaware corporation ("Endovasc
Delaware") and Endovasc, Inc. a Nevada corporation ("Endovasc Nevada") entered
into an Agreement and Plan of Merger ("Merger Agreement"). Endovasc Delaware and
Endovasc Nevada are referred to collectively herein as the "Parties". The
merger, which has been approved by the Board of Directors of each company was
approved by a majority of the holders of the issued and outstanding capital
stock of Endovasc Delaware on March 11, 2003 and became effective on March 31,
2003.
Upon the terms and subject to the conditions set forth in the Merger
Agreement and in accordance with Nevada Law, Endovasc Delaware shall be merged
with and into Endovasc Nevada. As a result of the merger, the outstanding shares
of capital stock of Endovasc Delaware shall be converted or canceled in the
manner provided in Section 2.01 of the Agreement, the separate corporate
existence of Endovasc Delaware shall cease, and Endovasc Nevada will be the
surviving corporation in the Merger.
For more information concerning the merger, please see (i) the Merger
Agreement which has been filed as an exhibit, and (ii) the information set forth
in the Information Statement, dated March 11, 2003 and filed with the Securities
ad Exchange Commission on March 11, 2003 pursuant to Section 14(c) of the
Securities Exchange Act of 1934 and SEC Rule 14C-2.
ITEM 2. FINANCIAL STATEMENTS AND EXHIBITS
- -----------------------------------------
Financial Statements
NONE
Exhibits
4 -- AGREEMENT AND PLAN OF MERGER
99.2 -- PRESS RELEASE
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ENDOVASC, INC.
(A NEVADA CORPORATION)
By:
-----------------------------------------
Dr. David P. Summers, President and Chief
Executive Officer
Date: March 31, 2003